Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 145, Issue 4, Pages 1031-1047Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2020.02.013
Keywords
Autoimmune bullous diseases; desmoglein; BP180; type XVII collagen BP230; ELISA; rituximab
Categories
Funding
- Health and Labor Sciences Research Grants for Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan [17933604]
- Japan Agency for Medical Research and Development [17824562, 19111560]
Ask authors/readers for more resources
Autoimmune bullous skin diseases, such as pemphigus and pemphigoid, may enable clarification of the mechanisms of immune regulation in the skin. Pemphigus and pemphigoid are mediated by essentially IgG autoantibodies against structural proteins of the desmosomes at cell-cell junctions and hemidesmosomes at epidermal-dermal junctions, respectively, and are characterized by blisters and erosions in the skin and/or mucous membranes. Intensive investigation over the last 3 decades has identified their target antigens and developed serological diagnostic tools as well as mouse models to help us understand their pathophysiology. Based on these advances, several new therapeutic approaches have become available, and more effective and less toxic targeted approaches are under development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available